2025
The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E
Ali M, Stockdale L, Sagara I, Zongo I, Yerbanga R, Mahamar A, Nikièma F, Tapily A, Sompougdou F, Diarra M, Bellamy D, Provstgaard-Morys S, Zoungrana C, Issiaka D, Haro A, Sanogo K, Sienou A, Kaya M, Traore S, Dicko O, Kone Y, Yalcouye H, Thera I, Diarra K, Snell P, Ofori-Anyinam O, Ockenhouse C, Lee C, Ewer K, Tinto H, Djimde A, Ouedraogo J, Dicko A, Chandramohan D, Greenwood B. The anti-circumsporozoite antibody response to repeated, seasonal booster doses of the malaria vaccine RTS,S/AS01E. Npj Vaccines 2025, 10: 26. PMID: 39915506, PMCID: PMC11802723, DOI: 10.1038/s41541-025-01078-0.Peer-Reviewed Original ResearchDoses of RTS,S/AS01RTS,S/AS01Dose of vaccineBooster dose of vaccineBooster doseAntibody responseCircumsporozoite proteinMalaria-endemic areas of AfricaRTS,S/AS01E malaria vaccineAntibody titresAnti-CSP antibody responsesBurden of malariaMalaria transmission seasonMalaria-endemic areasAnti-CSP antibodiesPlasmodium falciparum sporozoitesRisk of malariaMalaria vaccine RTS,S/AS01Incidence of malariaAssociated with protectionMultiplex assayYears of ageSevere malariaMalaria vaccineS/AS01
2024
The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study
Schmit N, Topazian H, Natama H, Bellamy D, Traoré O, Somé M, Rouamba T, Tahita M, Bonko M, Sourabié A, Sorgho H, Stockdale L, Provstgaard-Morys S, Aboagye J, Woods D, Rapi K, Datoo M, Lopez F, Charles G, McCain K, Ouedraogo J, Hamaluba M, Olotu A, Dicko A, Tinto H, Hill A, Ewer K, Ghani A, Winskill P. The public health impact and cost-effectiveness of the R21/Matrix-M malaria vaccine: a mathematical modelling study. The Lancet Infectious Diseases 2024, 24: 465-475. PMID: 38342107, DOI: 10.1016/s1473-3099(23)00816-2.Peer-Reviewed Original ResearchDisability-adjusted life yearsClinical malariaMalaria vaccineClinical casesVaccine introductionVaccinated childrenVaccine efficacyYears of follow-upPhase 2b trialPhase 3 trialSub-Saharan AfricaSurrogate of protectionIncremental costAntibody titresPublic health impactSerum Institute of IndiaBill &Cost-effectiveness ratioChildren aged 2Dose pricesMalaria deathsMelinda Gates FoundationNIHR Oxford Biomedical Research CentreFollow-upUK Medical Research Council
1990
Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso).
Guiguemdé T, Sturchler D, Ouédraogo J, Drabo M, Etlinger H, Douchet C, Gbary A, Haller L, Kambou S, Fernex M. Vaccination against malaria: initial trial with an ant-sporozoite vaccine, (NANP)3-TT (RO 40-2361) in Africa (Bobo-Dioulasso, Burkina Faso). Bulletin De La Société De Pathologie Exotique 1990, 83: 217-27. PMID: 2119897.Peer-Reviewed Original ResearchConceptsDoses of TTAntibody titresCircumsporozoite proteinAverage antibody titresPeak IgG responseMonths of ageClinical malariaIgG responsesSystemic reactionsProtective efficacyVaccine trialsImmunological statusImmunisation vaccinesTetanus toxoidProtective effectGroup IIMalaria transmissionDay 0VaccineGroup IGroup IIIPlasmodium falciparumDay 75MalariaDay 150
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply